PLGA-Based Nanoplatforms in Drug Delivery for Inhibition and Destruction of Microbial Biofilm Article Swipe
Aref Shariati
,
Zahra Chegini
,
Ehsanollah Ghaznavi‐Rad
,
Ehsan Nazarzadeh Zare
,
Seyed Mostafa Hosseini
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.3389/fcimb.2022.926363
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.3389/fcimb.2022.926363
The biofilm community of microorganisms has been identified as the dominant mode of microbial growth in nature and a common characteristic of different microorganisms such as Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis. The biofilm structure helps in the protection from environmental threats including host immune system and antimicrobial agents. Thus, the biofilm community has led to a higher prevalence of multidrug-resistant (MDR) strains in recent years. In this regard, the use of a new class of antibiotics, natural compounds, and anti-biofilm enzymes has been considered for the destruction of the microbial biofilm. However, different drawbacks such as low penetration, high susceptibility to degradation, instability, and poor solubility in aqueous solutions limit the use of anti-biofilm agents (ABAs) in a clinical setting. As such, recent studies have been using poly lactic- co -glycolic acid (PLGA)-based nanoplatforms (PLGA NPFs) for delivery of ABAs that have reported promising results. These particles, due to proper drug loading and release kinetics, could suppress microbial attachment, colonization, and biofilm formation for a long time. Additionally, PLGA NPFs, because of the high drug-loading efficiencies, hydrophilic surface, negative charge, and electrostatic interaction, lead to effective penetration of antibiotics to the deeper layer of the biofilm, thereby eliminating the microbial biofilm. Thus, PLGA NPFs could be considered as a potential candidate for coating catheters and other medical material surfaces for inhibition and destruction of the microbial biofilm. However, the exact interaction of PLGA NPFs and the microbial biofilm should be evaluated in animal studies. Additionally, a future goal will be to develop PLGA formulations as systems that can be used for the treatment of the MDR microbial biofilm, since the exact interactions of PLGA NPFs and these biofilm structures are not elucidated. In the present review article, we have discussed various aspects of PLGA usage for inhibition and destruction of the microbial biofilm along with different methods and procedures that have been used for improving PLGA NPF efficacy against the microbial biofilm.
Related Topics
Concepts
Biofilm
Microbiology
Staphylococcus epidermidis
Pseudomonas aeruginosa
PLGA
Antimicrobial
Antibiotics
Chemistry
Staphylococcus aureus
Bacteria
Biology
In vitro
Biochemistry
Genetics
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.3389/fcimb.2022.926363
- https://www.frontiersin.org/articles/10.3389/fcimb.2022.926363/pdf
- OA Status
- gold
- Cited By
- 57
- References
- 135
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4283216752
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4283216752Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3389/fcimb.2022.926363Digital Object Identifier
- Title
-
PLGA-Based Nanoplatforms in Drug Delivery for Inhibition and Destruction of Microbial BiofilmWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-06-21Full publication date if available
- Authors
-
Aref Shariati, Zahra Chegini, Ehsanollah Ghaznavi‐Rad, Ehsan Nazarzadeh Zare, Seyed Mostafa HosseiniList of authors in order
- Landing page
-
https://doi.org/10.3389/fcimb.2022.926363Publisher landing page
- PDF URL
-
https://www.frontiersin.org/articles/10.3389/fcimb.2022.926363/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.frontiersin.org/articles/10.3389/fcimb.2022.926363/pdfDirect OA link when available
- Concepts
-
Biofilm, Microbiology, Staphylococcus epidermidis, Pseudomonas aeruginosa, PLGA, Antimicrobial, Antibiotics, Chemistry, Staphylococcus aureus, Bacteria, Biology, In vitro, Biochemistry, GeneticsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
57Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 27, 2024: 16, 2023: 12, 2022: 2Per-year citation counts (last 5 years)
- References (count)
-
135Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4283216752 |
|---|---|
| doi | https://doi.org/10.3389/fcimb.2022.926363 |
| ids.doi | https://doi.org/10.3389/fcimb.2022.926363 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/35800390 |
| ids.openalex | https://openalex.org/W4283216752 |
| fwci | 6.92684891 |
| mesh[0].qualifier_ui | Q000737 |
| mesh[0].descriptor_ui | D000900 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | chemistry |
| mesh[0].descriptor_name | Anti-Bacterial Agents |
| mesh[1].qualifier_ui | Q000494 |
| mesh[1].descriptor_ui | D000900 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | pharmacology |
| mesh[1].descriptor_name | Anti-Bacterial Agents |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D018441 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Biofilms |
| mesh[3].qualifier_ui | Q000494 |
| mesh[3].descriptor_ui | D006018 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | pharmacology |
| mesh[3].descriptor_name | Glycols |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D008826 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Microbial Sensitivity Tests |
| mesh[5].qualifier_ui | Q000737 |
| mesh[5].descriptor_ui | D000077182 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | chemistry |
| mesh[5].descriptor_name | Polylactic Acid-Polyglycolic Acid Copolymer |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D011550 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Pseudomonas aeruginosa |
| mesh[7].qualifier_ui | Q000737 |
| mesh[7].descriptor_ui | D000900 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | chemistry |
| mesh[7].descriptor_name | Anti-Bacterial Agents |
| mesh[8].qualifier_ui | Q000494 |
| mesh[8].descriptor_ui | D000900 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | pharmacology |
| mesh[8].descriptor_name | Anti-Bacterial Agents |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D018441 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Biofilms |
| mesh[10].qualifier_ui | Q000494 |
| mesh[10].descriptor_ui | D006018 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | pharmacology |
| mesh[10].descriptor_name | Glycols |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D008826 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Microbial Sensitivity Tests |
| mesh[12].qualifier_ui | Q000737 |
| mesh[12].descriptor_ui | D000077182 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | chemistry |
| mesh[12].descriptor_name | Polylactic Acid-Polyglycolic Acid Copolymer |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D011550 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Pseudomonas aeruginosa |
| type | review |
| title | PLGA-Based Nanoplatforms in Drug Delivery for Inhibition and Destruction of Microbial Biofilm |
| biblio.issue | |
| biblio.volume | 12 |
| biblio.last_page | 926363 |
| biblio.first_page | 926363 |
| topics[0].id | https://openalex.org/T10920 |
| topics[0].field.id | https://openalex.org/fields/30 |
| topics[0].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/3003 |
| topics[0].subfield.display_name | Pharmaceutical Science |
| topics[0].display_name | Advanced Drug Delivery Systems |
| topics[1].id | https://openalex.org/T10593 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9991000294685364 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Bacterial biofilms and quorum sensing |
| topics[2].id | https://openalex.org/T11103 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.9987999796867371 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2404 |
| topics[2].subfield.display_name | Microbiology |
| topics[2].display_name | Antimicrobial Peptides and Activities |
| is_xpac | False |
| apc_list.value | 2950 |
| apc_list.currency | USD |
| apc_list.value_usd | 2950 |
| apc_paid.value | 2950 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2950 |
| concepts[0].id | https://openalex.org/C58123911 |
| concepts[0].level | 3 |
| concepts[0].score | 0.9702945947647095 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q467410 |
| concepts[0].display_name | Biofilm |
| concepts[1].id | https://openalex.org/C89423630 |
| concepts[1].level | 1 |
| concepts[1].score | 0.6891558766365051 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q7193 |
| concepts[1].display_name | Microbiology |
| concepts[2].id | https://openalex.org/C2777949923 |
| concepts[2].level | 4 |
| concepts[2].score | 0.6253621578216553 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q131915 |
| concepts[2].display_name | Staphylococcus epidermidis |
| concepts[3].id | https://openalex.org/C2777637488 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5831996202468872 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q31856 |
| concepts[3].display_name | Pseudomonas aeruginosa |
| concepts[4].id | https://openalex.org/C2780165375 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5132544040679932 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2102907 |
| concepts[4].display_name | PLGA |
| concepts[5].id | https://openalex.org/C4937899 |
| concepts[5].level | 2 |
| concepts[5].score | 0.49271252751350403 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q68541106 |
| concepts[5].display_name | Antimicrobial |
| concepts[6].id | https://openalex.org/C501593827 |
| concepts[6].level | 2 |
| concepts[6].score | 0.46636733412742615 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q12187 |
| concepts[6].display_name | Antibiotics |
| concepts[7].id | https://openalex.org/C185592680 |
| concepts[7].level | 0 |
| concepts[7].score | 0.43105483055114746 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[7].display_name | Chemistry |
| concepts[8].id | https://openalex.org/C2779489039 |
| concepts[8].level | 3 |
| concepts[8].score | 0.41206085681915283 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q188121 |
| concepts[8].display_name | Staphylococcus aureus |
| concepts[9].id | https://openalex.org/C523546767 |
| concepts[9].level | 2 |
| concepts[9].score | 0.3306288719177246 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q10876 |
| concepts[9].display_name | Bacteria |
| concepts[10].id | https://openalex.org/C86803240 |
| concepts[10].level | 0 |
| concepts[10].score | 0.2609708309173584 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[10].display_name | Biology |
| concepts[11].id | https://openalex.org/C202751555 |
| concepts[11].level | 2 |
| concepts[11].score | 0.13367551565170288 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q221681 |
| concepts[11].display_name | In vitro |
| concepts[12].id | https://openalex.org/C55493867 |
| concepts[12].level | 1 |
| concepts[12].score | 0.10140159726142883 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[12].display_name | Biochemistry |
| concepts[13].id | https://openalex.org/C54355233 |
| concepts[13].level | 1 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[13].display_name | Genetics |
| keywords[0].id | https://openalex.org/keywords/biofilm |
| keywords[0].score | 0.9702945947647095 |
| keywords[0].display_name | Biofilm |
| keywords[1].id | https://openalex.org/keywords/microbiology |
| keywords[1].score | 0.6891558766365051 |
| keywords[1].display_name | Microbiology |
| keywords[2].id | https://openalex.org/keywords/staphylococcus-epidermidis |
| keywords[2].score | 0.6253621578216553 |
| keywords[2].display_name | Staphylococcus epidermidis |
| keywords[3].id | https://openalex.org/keywords/pseudomonas-aeruginosa |
| keywords[3].score | 0.5831996202468872 |
| keywords[3].display_name | Pseudomonas aeruginosa |
| keywords[4].id | https://openalex.org/keywords/plga |
| keywords[4].score | 0.5132544040679932 |
| keywords[4].display_name | PLGA |
| keywords[5].id | https://openalex.org/keywords/antimicrobial |
| keywords[5].score | 0.49271252751350403 |
| keywords[5].display_name | Antimicrobial |
| keywords[6].id | https://openalex.org/keywords/antibiotics |
| keywords[6].score | 0.46636733412742615 |
| keywords[6].display_name | Antibiotics |
| keywords[7].id | https://openalex.org/keywords/chemistry |
| keywords[7].score | 0.43105483055114746 |
| keywords[7].display_name | Chemistry |
| keywords[8].id | https://openalex.org/keywords/staphylococcus-aureus |
| keywords[8].score | 0.41206085681915283 |
| keywords[8].display_name | Staphylococcus aureus |
| keywords[9].id | https://openalex.org/keywords/bacteria |
| keywords[9].score | 0.3306288719177246 |
| keywords[9].display_name | Bacteria |
| keywords[10].id | https://openalex.org/keywords/biology |
| keywords[10].score | 0.2609708309173584 |
| keywords[10].display_name | Biology |
| keywords[11].id | https://openalex.org/keywords/in-vitro |
| keywords[11].score | 0.13367551565170288 |
| keywords[11].display_name | In vitro |
| keywords[12].id | https://openalex.org/keywords/biochemistry |
| keywords[12].score | 0.10140159726142883 |
| keywords[12].display_name | Biochemistry |
| language | en |
| locations[0].id | doi:10.3389/fcimb.2022.926363 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2506667490 |
| locations[0].source.issn | 2235-2988 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2235-2988 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Frontiers in Cellular and Infection Microbiology |
| locations[0].source.host_organization | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_name | Frontiers Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_lineage_names | Frontiers Media |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.frontiersin.org/articles/10.3389/fcimb.2022.926363/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Frontiers in Cellular and Infection Microbiology |
| locations[0].landing_page_url | https://doi.org/10.3389/fcimb.2022.926363 |
| locations[1].id | pmid:35800390 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Frontiers in cellular and infection microbiology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/35800390 |
| locations[2].id | pmh:oai:doaj.org/article:b54c8d580cb84f95b718e6890bc5eff9 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Frontiers in Cellular and Infection Microbiology, Vol 12 (2022) |
| locations[2].landing_page_url | https://doaj.org/article/b54c8d580cb84f95b718e6890bc5eff9 |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:9253276 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Front Cell Infect Microbiol |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9253276 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5108033815 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Aref Shariati |
| authorships[0].countries | IR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2800596343 |
| authorships[0].affiliations[0].raw_affiliation_string | Molecular and Medicine Research Center, Khomein University of Medical Sciences, Khomein, Iran |
| authorships[0].institutions[0].id | https://openalex.org/I2800596343 |
| authorships[0].institutions[0].ror | https://ror.org/05v2x6b69 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I2800596343, https://openalex.org/I70640408 |
| authorships[0].institutions[0].country_code | IR |
| authorships[0].institutions[0].display_name | Imam Khomeini Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Aref Shariati |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Molecular and Medicine Research Center, Khomein University of Medical Sciences, Khomein, Iran |
| authorships[1].author.id | https://openalex.org/A5002085984 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-2382-3846 |
| authorships[1].author.display_name | Zahra Chegini |
| authorships[1].countries | IR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I112312016 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran |
| authorships[1].institutions[0].id | https://openalex.org/I112312016 |
| authorships[1].institutions[0].ror | https://ror.org/02ekfbp48 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I112312016 |
| authorships[1].institutions[0].country_code | IR |
| authorships[1].institutions[0].display_name | Hamedan University of Medical Sciences |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Zahra Chegini |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran |
| authorships[2].author.id | https://openalex.org/A5080698288 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-8484-7166 |
| authorships[2].author.display_name | Ehsanollah Ghaznavi‐Rad |
| authorships[2].countries | IR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I133903919 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Microbiology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran |
| authorships[2].institutions[0].id | https://openalex.org/I133903919 |
| authorships[2].institutions[0].ror | https://ror.org/056mgfb42 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I133903919 |
| authorships[2].institutions[0].country_code | IR |
| authorships[2].institutions[0].display_name | Arak University of Medical Sciences |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Ehsanollah Ghaznavi-Rad |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Microbiology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran |
| authorships[3].author.id | https://openalex.org/A5023671985 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-0446-4385 |
| authorships[3].author.display_name | Ehsan Nazarzadeh Zare |
| authorships[3].countries | IR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I192805215 |
| authorships[3].affiliations[0].raw_affiliation_string | School of Chemistry, Damghan University, 36716-41167, Damghan, Iran |
| authorships[3].institutions[0].id | https://openalex.org/I192805215 |
| authorships[3].institutions[0].ror | https://ror.org/03v4m1x12 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I192805215 |
| authorships[3].institutions[0].country_code | IR |
| authorships[3].institutions[0].display_name | Damghan University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Ehsan Nazarzadeh Zare |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | School of Chemistry, Damghan University, 36716-41167, Damghan, Iran |
| authorships[4].author.id | https://openalex.org/A5037003333 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-2604-504X |
| authorships[4].author.display_name | Seyed Mostafa Hosseini |
| authorships[4].countries | IR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I112312016 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran |
| authorships[4].institutions[0].id | https://openalex.org/I112312016 |
| authorships[4].institutions[0].ror | https://ror.org/02ekfbp48 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I112312016 |
| authorships[4].institutions[0].country_code | IR |
| authorships[4].institutions[0].display_name | Hamedan University of Medical Sciences |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Seyed Mostafa Hosseini |
| authorships[4].is_corresponding | True |
| authorships[4].raw_affiliation_strings | Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.frontiersin.org/articles/10.3389/fcimb.2022.926363/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | PLGA-Based Nanoplatforms in Drug Delivery for Inhibition and Destruction of Microbial Biofilm |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10920 |
| primary_topic.field.id | https://openalex.org/fields/30 |
| primary_topic.field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/3003 |
| primary_topic.subfield.display_name | Pharmaceutical Science |
| primary_topic.display_name | Advanced Drug Delivery Systems |
| related_works | https://openalex.org/W1931108325, https://openalex.org/W2156716055, https://openalex.org/W2096169300, https://openalex.org/W3173391969, https://openalex.org/W2909075475, https://openalex.org/W2988260234, https://openalex.org/W4200488327, https://openalex.org/W3037491291, https://openalex.org/W2993156972, https://openalex.org/W3097661805 |
| cited_by_count | 57 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 27 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 16 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 12 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 2 |
| locations_count | 4 |
| best_oa_location.id | doi:10.3389/fcimb.2022.926363 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2506667490 |
| best_oa_location.source.issn | 2235-2988 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2235-2988 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Frontiers in Cellular and Infection Microbiology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_name | Frontiers Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_lineage_names | Frontiers Media |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.frontiersin.org/articles/10.3389/fcimb.2022.926363/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Frontiers in Cellular and Infection Microbiology |
| best_oa_location.landing_page_url | https://doi.org/10.3389/fcimb.2022.926363 |
| primary_location.id | doi:10.3389/fcimb.2022.926363 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2506667490 |
| primary_location.source.issn | 2235-2988 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2235-2988 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Frontiers in Cellular and Infection Microbiology |
| primary_location.source.host_organization | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_name | Frontiers Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_lineage_names | Frontiers Media |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.frontiersin.org/articles/10.3389/fcimb.2022.926363/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Frontiers in Cellular and Infection Microbiology |
| primary_location.landing_page_url | https://doi.org/10.3389/fcimb.2022.926363 |
| publication_date | 2022-06-21 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W1960558965, https://openalex.org/W3123632916, https://openalex.org/W3014229067, https://openalex.org/W2999035884, https://openalex.org/W2046627126, https://openalex.org/W2996468770, https://openalex.org/W2038597110, https://openalex.org/W2535779351, https://openalex.org/W2047368765, https://openalex.org/W2072790070, https://openalex.org/W2910414258, https://openalex.org/W2946091336, https://openalex.org/W2946032810, https://openalex.org/W3155698469, https://openalex.org/W1975669261, https://openalex.org/W1991642756, https://openalex.org/W2155417329, https://openalex.org/W2767479323, https://openalex.org/W2134495764, https://openalex.org/W2038200149, https://openalex.org/W1988144016, https://openalex.org/W3177912973, https://openalex.org/W1183649710, https://openalex.org/W2020398834, https://openalex.org/W2996352810, https://openalex.org/W2997278986, https://openalex.org/W2782405156, https://openalex.org/W4210534330, https://openalex.org/W3014140358, https://openalex.org/W2884837183, https://openalex.org/W2895739127, https://openalex.org/W2888466586, https://openalex.org/W3033601302, https://openalex.org/W2291892352, https://openalex.org/W2027725351, https://openalex.org/W3186204252, https://openalex.org/W4200393513, https://openalex.org/W1987391674, https://openalex.org/W1840976068, https://openalex.org/W2117497530, https://openalex.org/W2017560821, https://openalex.org/W3017013087, https://openalex.org/W3189659325, https://openalex.org/W2075226895, https://openalex.org/W2973800225, https://openalex.org/W2557184343, https://openalex.org/W2945327005, https://openalex.org/W2571415415, https://openalex.org/W2943405955, https://openalex.org/W2987638966, https://openalex.org/W4200549229, https://openalex.org/W3027379856, https://openalex.org/W2044413427, https://openalex.org/W2991200623, https://openalex.org/W2062726720, https://openalex.org/W2022981155, https://openalex.org/W1975780688, https://openalex.org/W2670981167, https://openalex.org/W2344598639, https://openalex.org/W2914780822, https://openalex.org/W2548795614, https://openalex.org/W1965451682, https://openalex.org/W2964982029, https://openalex.org/W3092755311, https://openalex.org/W2759232158, https://openalex.org/W3015601786, https://openalex.org/W2009255575, https://openalex.org/W2043346930, https://openalex.org/W2890362631, https://openalex.org/W3002585265, https://openalex.org/W2913736889, https://openalex.org/W2297183188, https://openalex.org/W2800301065, https://openalex.org/W3012582624, https://openalex.org/W2972260241, https://openalex.org/W3107980541, https://openalex.org/W4210302584, https://openalex.org/W2998743749, https://openalex.org/W2993111357, https://openalex.org/W1975880946, https://openalex.org/W3110998013, https://openalex.org/W6807617732, https://openalex.org/W1997870581, https://openalex.org/W2041838926, https://openalex.org/W3171433358, https://openalex.org/W2888699528, https://openalex.org/W3208573039, https://openalex.org/W2890167612, https://openalex.org/W4212773454, https://openalex.org/W2835980273, https://openalex.org/W2946149975, https://openalex.org/W2512614165, https://openalex.org/W2755341502, https://openalex.org/W2035523428, https://openalex.org/W3211805452, https://openalex.org/W3092947717, https://openalex.org/W4213375685, https://openalex.org/W2081229118, https://openalex.org/W2579507237, https://openalex.org/W1984162012, https://openalex.org/W1993999157, https://openalex.org/W3187032487, https://openalex.org/W1985346406, https://openalex.org/W1972624254, https://openalex.org/W2979812179, https://openalex.org/W3022410933, https://openalex.org/W2947981654, https://openalex.org/W3214114314, https://openalex.org/W2970857608, https://openalex.org/W3162062861, https://openalex.org/W2039776416, https://openalex.org/W2061878956, https://openalex.org/W2125603952, https://openalex.org/W2797789122, https://openalex.org/W6638991482, https://openalex.org/W2903293966, https://openalex.org/W2557094147, https://openalex.org/W2164313649, https://openalex.org/W3153380879, https://openalex.org/W2001875667, https://openalex.org/W2583700544, https://openalex.org/W2993031049, https://openalex.org/W3109031471, https://openalex.org/W2041985711, https://openalex.org/W2778198694, https://openalex.org/W3158368997, https://openalex.org/W4200284860, https://openalex.org/W3097566065, https://openalex.org/W2923561970, https://openalex.org/W2998058902, https://openalex.org/W3118459981, https://openalex.org/W2902095884, https://openalex.org/W2140578021, https://openalex.org/W3200761386, https://openalex.org/W3033126474 |
| referenced_works_count | 135 |
| abstract_inverted_index.a | 18, 57, 73, 119, 166, 210, 247 |
| abstract_inverted_index.As | 122 |
| abstract_inverted_index.In | 67, 284 |
| abstract_inverted_index.as | 8, 25, 97, 209, 256 |
| abstract_inverted_index.be | 207, 241, 251, 260 |
| abstract_inverted_index.co | 131 |
| abstract_inverted_index.in | 15, 37, 64, 108, 118, 243 |
| abstract_inverted_index.of | 3, 12, 21, 60, 72, 76, 89, 114, 140, 173, 189, 195, 225, 233, 265, 274, 294, 301 |
| abstract_inverted_index.to | 56, 102, 150, 186, 191, 252 |
| abstract_inverted_index.we | 289 |
| abstract_inverted_index.MDR | 267 |
| abstract_inverted_index.NPF | 318 |
| abstract_inverted_index.The | 0, 33 |
| abstract_inverted_index.and | 17, 30, 47, 80, 105, 154, 162, 182, 216, 223, 236, 277, 299, 309 |
| abstract_inverted_index.are | 281 |
| abstract_inverted_index.can | 259 |
| abstract_inverted_index.due | 149 |
| abstract_inverted_index.for | 86, 138, 165, 213, 221, 262, 297, 315 |
| abstract_inverted_index.has | 5, 54, 83 |
| abstract_inverted_index.led | 55 |
| abstract_inverted_index.low | 98 |
| abstract_inverted_index.new | 74 |
| abstract_inverted_index.not | 282 |
| abstract_inverted_index.the | 9, 38, 51, 70, 87, 90, 112, 174, 192, 196, 200, 226, 230, 237, 263, 266, 271, 285, 302, 321 |
| abstract_inverted_index.use | 71, 113 |
| abstract_inverted_index.ABAs | 141 |
| abstract_inverted_index.NPFs | 205, 235, 276 |
| abstract_inverted_index.PLGA | 170, 204, 234, 254, 275, 295, 317 |
| abstract_inverted_index.acid | 133 |
| abstract_inverted_index.been | 6, 84, 127, 313 |
| abstract_inverted_index.drug | 152 |
| abstract_inverted_index.from | 40 |
| abstract_inverted_index.goal | 249 |
| abstract_inverted_index.have | 126, 143, 290, 312 |
| abstract_inverted_index.high | 100, 175 |
| abstract_inverted_index.host | 44 |
| abstract_inverted_index.lead | 185 |
| abstract_inverted_index.long | 167 |
| abstract_inverted_index.mode | 11 |
| abstract_inverted_index.poly | 129 |
| abstract_inverted_index.poor | 106 |
| abstract_inverted_index.such | 24, 96 |
| abstract_inverted_index.that | 142, 258, 311 |
| abstract_inverted_index.this | 68 |
| abstract_inverted_index.used | 261, 314 |
| abstract_inverted_index.will | 250 |
| abstract_inverted_index.with | 306 |
| abstract_inverted_index.(MDR) | 62 |
| abstract_inverted_index.(PLGA | 136 |
| abstract_inverted_index.NPFs) | 137 |
| abstract_inverted_index.NPFs, | 171 |
| abstract_inverted_index.These | 147 |
| abstract_inverted_index.Thus, | 50, 203 |
| abstract_inverted_index.along | 305 |
| abstract_inverted_index.class | 75 |
| abstract_inverted_index.could | 157, 206 |
| abstract_inverted_index.exact | 231, 272 |
| abstract_inverted_index.helps | 36 |
| abstract_inverted_index.layer | 194 |
| abstract_inverted_index.limit | 111 |
| abstract_inverted_index.other | 217 |
| abstract_inverted_index.since | 270 |
| abstract_inverted_index.such, | 123 |
| abstract_inverted_index.these | 278 |
| abstract_inverted_index.time. | 168 |
| abstract_inverted_index.usage | 296 |
| abstract_inverted_index.using | 128 |
| abstract_inverted_index.(ABAs) | 117 |
| abstract_inverted_index.agents | 116 |
| abstract_inverted_index.animal | 244 |
| abstract_inverted_index.common | 19 |
| abstract_inverted_index.deeper | 193 |
| abstract_inverted_index.future | 248 |
| abstract_inverted_index.growth | 14 |
| abstract_inverted_index.higher | 58 |
| abstract_inverted_index.immune | 45 |
| abstract_inverted_index.nature | 16 |
| abstract_inverted_index.proper | 151 |
| abstract_inverted_index.recent | 65, 124 |
| abstract_inverted_index.review | 287 |
| abstract_inverted_index.should | 240 |
| abstract_inverted_index.system | 46 |
| abstract_inverted_index.years. | 66 |
| abstract_inverted_index.against | 320 |
| abstract_inverted_index.agents. | 49 |
| abstract_inverted_index.aqueous | 109 |
| abstract_inverted_index.aspects | 293 |
| abstract_inverted_index.aureus, | 29 |
| abstract_inverted_index.because | 172 |
| abstract_inverted_index.biofilm | 1, 34, 52, 163, 239, 279, 304 |
| abstract_inverted_index.charge, | 181 |
| abstract_inverted_index.coating | 214 |
| abstract_inverted_index.develop | 253 |
| abstract_inverted_index.enzymes | 82 |
| abstract_inverted_index.lactic- | 130 |
| abstract_inverted_index.loading | 153 |
| abstract_inverted_index.medical | 218 |
| abstract_inverted_index.methods | 308 |
| abstract_inverted_index.natural | 78 |
| abstract_inverted_index.present | 286 |
| abstract_inverted_index.regard, | 69 |
| abstract_inverted_index.release | 155 |
| abstract_inverted_index.strains | 63 |
| abstract_inverted_index.studies | 125 |
| abstract_inverted_index.systems | 257 |
| abstract_inverted_index.thereby | 198 |
| abstract_inverted_index.threats | 42 |
| abstract_inverted_index.various | 292 |
| abstract_inverted_index.However, | 93, 229 |
| abstract_inverted_index.article, | 288 |
| abstract_inverted_index.biofilm, | 197, 269 |
| abstract_inverted_index.biofilm. | 92, 202, 228, 323 |
| abstract_inverted_index.clinical | 120 |
| abstract_inverted_index.delivery | 139 |
| abstract_inverted_index.dominant | 10 |
| abstract_inverted_index.efficacy | 319 |
| abstract_inverted_index.material | 219 |
| abstract_inverted_index.negative | 180 |
| abstract_inverted_index.reported | 144 |
| abstract_inverted_index.results. | 146 |
| abstract_inverted_index.setting. | 121 |
| abstract_inverted_index.studies. | 245 |
| abstract_inverted_index.suppress | 158 |
| abstract_inverted_index.surface, | 179 |
| abstract_inverted_index.surfaces | 220 |
| abstract_inverted_index.-glycolic | 132 |
| abstract_inverted_index.candidate | 212 |
| abstract_inverted_index.catheters | 215 |
| abstract_inverted_index.community | 2, 53 |
| abstract_inverted_index.different | 22, 94, 307 |
| abstract_inverted_index.discussed | 291 |
| abstract_inverted_index.drawbacks | 95 |
| abstract_inverted_index.effective | 187 |
| abstract_inverted_index.evaluated | 242 |
| abstract_inverted_index.formation | 164 |
| abstract_inverted_index.improving | 316 |
| abstract_inverted_index.including | 43 |
| abstract_inverted_index.kinetics, | 156 |
| abstract_inverted_index.microbial | 13, 91, 159, 201, 227, 238, 268, 303, 322 |
| abstract_inverted_index.potential | 211 |
| abstract_inverted_index.promising | 145 |
| abstract_inverted_index.solutions | 110 |
| abstract_inverted_index.structure | 35 |
| abstract_inverted_index.treatment | 264 |
| abstract_inverted_index.compounds, | 79 |
| abstract_inverted_index.considered | 85, 208 |
| abstract_inverted_index.identified | 7 |
| abstract_inverted_index.inhibition | 222, 298 |
| abstract_inverted_index.particles, | 148 |
| abstract_inverted_index.prevalence | 59 |
| abstract_inverted_index.procedures | 310 |
| abstract_inverted_index.protection | 39 |
| abstract_inverted_index.solubility | 107 |
| abstract_inverted_index.structures | 280 |
| abstract_inverted_index.Pseudomonas | 26 |
| abstract_inverted_index.aeruginosa, | 27 |
| abstract_inverted_index.antibiotics | 190 |
| abstract_inverted_index.attachment, | 160 |
| abstract_inverted_index.destruction | 88, 224, 300 |
| abstract_inverted_index.eliminating | 199 |
| abstract_inverted_index.elucidated. | 283 |
| abstract_inverted_index.hydrophilic | 178 |
| abstract_inverted_index.interaction | 232 |
| abstract_inverted_index.penetration | 188 |
| abstract_inverted_index.(PLGA)-based | 134 |
| abstract_inverted_index.anti-biofilm | 81, 115 |
| abstract_inverted_index.antibiotics, | 77 |
| abstract_inverted_index.degradation, | 103 |
| abstract_inverted_index.drug-loading | 176 |
| abstract_inverted_index.epidermidis. | 32 |
| abstract_inverted_index.formulations | 255 |
| abstract_inverted_index.instability, | 104 |
| abstract_inverted_index.interaction, | 184 |
| abstract_inverted_index.interactions | 273 |
| abstract_inverted_index.penetration, | 99 |
| abstract_inverted_index.Additionally, | 169, 246 |
| abstract_inverted_index.antimicrobial | 48 |
| abstract_inverted_index.colonization, | 161 |
| abstract_inverted_index.efficiencies, | 177 |
| abstract_inverted_index.electrostatic | 183 |
| abstract_inverted_index.environmental | 41 |
| abstract_inverted_index.nanoplatforms | 135 |
| abstract_inverted_index.Staphylococcus | 28, 31 |
| abstract_inverted_index.characteristic | 20 |
| abstract_inverted_index.microorganisms | 4, 23 |
| abstract_inverted_index.susceptibility | 101 |
| abstract_inverted_index.multidrug-resistant | 61 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 94 |
| corresponding_author_ids | https://openalex.org/A5037003333 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 5 |
| corresponding_institution_ids | https://openalex.org/I112312016 |
| citation_normalized_percentile.value | 0.96942467 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |